The Cannabis Investing Podcast
Investing In cannabis? Stay patient, be ready
Jan 4, 2024
Chris DeMuth likes the opportunity in cannabis, Julian Lin talks about M&A and disappointment, Alan Brochstein waits for catalysts, Jesse Redmond discusses the best way to invest, Emily Paxhia focuses on SG&A containment and using the right metrics
21:10
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The potential rescheduling of cannabis as a schedule one drug by the DEA presents promising investment opportunities in the cannabis industry.
- Investors should focus on quality companies, strategic long-term investments, and understanding market dynamics when navigating the complex cannabis market.
Deep dives
Reconsidering Cannabis's Status
The DEA is reconsidering cannabis's status as a schedule one drug, which is generating optimism among cannabis investors. This potential shift in classification could have significant implications for the cannabis industry, leading to increased investment opportunities and growth potential. The current cultural and political climate, along with the desire to address civil liberty concerns and generate revenue, support the argument for the eventual rescheduling of cannabis. While specific timing remains uncertain, this development holds promise for investors looking to capitalize on the future potential of the cannabis market.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
